UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in

The purpose of this study is to learn more about the safety and effects of Kalyedco in subjects with CF who are 6 years old and older, with at least one copy of the R117H-CFTR mutation.  We will also look at how Kalyedco may affect your body and how your body breaks down and eliminates ivacaftor. 

Start Date
February 18, 2013
End Date
August 22, 2014
Gender Preference
Age Group
6 - 99 years
Principal Investigator
Richard Ahrens, MD
Contact Info

Mary Teresi PharmD  mary-teresi@uiowa.edu

Cystic Fibrosis ; R117H genotype ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.